Sensydia's core product, the Cardiac Performance System (CPS), pairs ultra-sensitive biosensors with AI and proprietary waveform machine-learning to deliver rapid, non-invasive measurements of ejection fraction, cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure in under five minutes. CPS has been trained against gold-standard in-hospital catheterization lab data. The company received FDA 510(k) clearance in 2018 for non-invasive measurement of ejection fraction and earned Breakthrough Device Designation in 2022. Sensydia plans to finalize CPS development and submit to the U.S. FDA in 2024 for prioritized review under the Breakthrough Devices Program. The platform is positioned to expand cardiac performance assessment outside hospital catheterization labs, aiming to lower costs and broaden access to care. The recently announced financing will support commercialization preparation and expanded development and operations.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

May 2023